Patents Assigned to Cell Genesys
  • Publication number: 20100317096
    Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.
    Type: Application
    Filed: October 26, 2007
    Publication date: December 16, 2010
    Applicant: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
  • Publication number: 20100150946
    Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Application
    Filed: August 24, 2009
    Publication date: June 17, 2010
    Applicant: Cell Genesys, Inc.
    Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
  • Publication number: 20100151523
    Abstract: Single AAV vector constructs for regulated expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a regulated promoter operably linked to the coding sequence for a first and second immunoglobulin coding sequence, a sequence encoding a self-processing cleavage site between the coding sequence for the first and second immunoglobulin coding sequence and a additional proteolytic cleavage site, which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.
    Type: Application
    Filed: June 30, 2009
    Publication date: June 17, 2010
    Applicants: CELL GENESYS, INC., ARIAD PHARMACEUTICALS, INC.
    Inventors: JIANMIN FANG, KARIN JOOSS, MINH NGUYEN, THOMAS C. HARDING, TIMOTHY P. CLACKSON, VICTOR M. RIVERA
  • Publication number: 20090297483
    Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.
    Type: Application
    Filed: November 21, 2007
    Publication date: December 3, 2009
    Applicant: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
  • Publication number: 20090270485
    Abstract: Cell specific replication-competent viral vectors comprising a self processing peptide cleavage sequence are provided. The targeted replication-competent viral vectors include two or more co-transcribed genes under transcriptional control of the same heterologous transcriptional regulatory element (TRE), wherein at least a second gene is under translational control of a self processing cleavage sequence or 2A sequence. Exemplary vector constructs may further include an additional proteolytic cleavage site which provides a means to remove the self processing peptide sequence from the viral vector.
    Type: Application
    Filed: July 24, 2008
    Publication date: October 29, 2009
    Applicant: CELL GENESYS, INC.
    Inventors: Derek Ko, Yuanhao Li, Thomas Harding, Jianmin Fang, Nagarajan Ramesh, De-Chao Yu
  • Patent number: 7575919
    Abstract: The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: August 18, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: De-Chao Yu, Daniel R. Henderson
  • Publication number: 20090156796
    Abstract: Colon cancer specific promoter sequences and adenovirus vehicles are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 18, 2009
    Applicant: Cell Genesys, Inc.
    Inventors: Yuanhao Li, De-Chao Yu
  • Publication number: 20090130054
    Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Application
    Filed: August 29, 2008
    Publication date: May 21, 2009
    Applicants: Cell Genesys, Inc., Immutep S.A.
    Inventors: Karin Jooss, Betty Li, Frederic Triebel
  • Publication number: 20090099125
    Abstract: Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in the treatment of cancer.
    Type: Application
    Filed: December 4, 2008
    Publication date: April 16, 2009
    Applicant: Cell Genesys, Inc.
    Inventors: DeChao Yu, Yuanhao Li
  • Patent number: 7498024
    Abstract: Single vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in methods for enhanced production of biologically active immunoglobulins or fragments thereof in vitro or in vivo.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: March 3, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
  • Publication number: 20090053750
    Abstract: The present invention relates to filamin-B peptides, compositions comprising such peptides, and methods of using such peptides to assess an immune response against such peptides. An immune response against the peptides correlates with an immune response, in particular a cellular immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Application
    Filed: July 26, 2007
    Publication date: February 26, 2009
    Applicant: Cell Genesys, Inc.
    Inventors: Jooeun Bae, Karin Jooss
  • Patent number: 7485291
    Abstract: Single vector constructs for expression of a functional antibody molecule are described. The vectors have a self-processing cleavage site between two heterologous DNA coding sequences allowing for expression of two coding sequences using a single promoter. Exemplary vector constructs comprise a foot and mouth disease virus (FMDV) 2A sequence. The vector constructs can be used in methods relating to antibody delivery and therapy and in the production of a biologically active antibody or fragment thereof.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: February 3, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
  • Publication number: 20090028857
    Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Application
    Filed: July 23, 2008
    Publication date: January 29, 2009
    Applicant: CELL GENESYS, INC.
    Inventors: Betty Li, Karin Jooss, Alan J. Korman
  • Patent number: 7482156
    Abstract: Liver cancer, particularly hepatocellular carcinoma specific promoter sequences and adenovirus vehicles are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity, for treating neoplasia.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: January 27, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: Trini Arroyo, Yuanhao Li
  • Patent number: 7473418
    Abstract: Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in the treatment of cancer.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: January 6, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: DeChao Yu, Yuanhao Li
  • Patent number: 7459154
    Abstract: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.
    Type: Grant
    Filed: December 26, 2002
    Date of Patent: December 2, 2008
    Assignee: Cell Genesys, Inc.
    Inventors: Nagarajan Ramesh, David Frey, Bahram Memarzadeh, DeChao Yu
  • Publication number: 20080286836
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Application
    Filed: July 26, 2006
    Publication date: November 20, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Publication number: 20080279831
    Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Application
    Filed: March 3, 2008
    Publication date: November 13, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
  • Publication number: 20080280356
    Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.
    Type: Application
    Filed: October 26, 2007
    Publication date: November 13, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
  • Publication number: 20080267935
    Abstract: The present invention provides improved method of cancer therapy in a mammal. More particularly, the invention is concerned with systems comprising cytosine arabinoside (AraC) and a cytokine-expressing cancer immunotherapy composition and methods of administering the combination to cancer patients in order to generate an immune response against the cancer and provide treatment with therapeutic efficacy that is an improvement relative to administration of AraC or the cytokine-expressing cancer immunotherapy composition alone as a monotherapy.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 30, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: JianMin Lin, Betty Li, Eric Rimmer, Melinda Van Roey, Karin Jooss